BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abdelmageed MI, Abdelmoneim AH, Mustafa MI, Elfadol NM, Murshed NS, Shantier SW, Makhawi AM. Design of a Multiepitope-Based Peptide Vaccine against the E Protein of Human COVID-19: An Immunoinformatics Approach. Biomed Res Int 2020;2020:2683286. [PMID: 32461973 DOI: 10.1155/2020/2683286] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 28.0] [Reference Citation Analysis]
Number Citing Articles
1 TopuzoĞullari M, Acar T, Pelİt Arayici P, UÇar B, UĞurel E, Abamor EŞ, ArasoĞlu T, Turgut-Balik D, Derman S. An insight into the epitope-based peptide vaccine design strategy and studies against COVID-19. Turk J Biol 2020;44:215-27. [PMID: 32595358 DOI: 10.3906/biy-2006-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
2 Basu S, Ramaiah S, Anbarasu A. In-silico strategies to combat COVID-19: A comprehensive review. Biotechnol Genet Eng Rev 2021;37:64-81. [PMID: 34470564 DOI: 10.1080/02648725.2021.1966920] [Reference Citation Analysis]
3 Singh A, Thakur M, Sharma LK, Chandra K. Designing a multi-epitope peptide based vaccine against SARS-CoV-2. Sci Rep 2020;10:16219. [PMID: 33004978 DOI: 10.1038/s41598-020-73371-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
4 Nel AE, Miller JF. Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape. ACS Nano 2021;15:5793-818. [PMID: 33793189 DOI: 10.1021/acsnano.1c01845] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
5 Abdelmoneim AH, Mustafa MI, Abdelmageed MI, Murshed NS, Dawoud ED, Ahmed EM, Kamal Eldein RM, Elfadol NM, Sati AOM, Makhawi AM. Immunoinformatics design of multiepitopes peptide-based universal cancer vaccine using matrix metalloproteinase-9 protein as a target. Immunol Med 2021;44:35-52. [PMID: 32692610 DOI: 10.1080/25785826.2020.1794165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
6 Ishack S, Lipner SR. Bioinformatics and immunoinformatics to support COVID-19 vaccine development. J Med Virol 2021;93:5209-11. [PMID: 33851735 DOI: 10.1002/jmv.27017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Ita K. Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development. Arch Med Res 2021;52:15-24. [PMID: 32950264 DOI: 10.1016/j.arcmed.2020.09.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
8 Waqas M, Haider A, Rehman A, Qasim M, Umar A, Sufyan M, Akram HN, Mir A, Razzaq R, Rasool D, Tahir RA, Sehgal SA. Immunoinformatics and Molecular Docking Studies Predicted Potential Multiepitope-Based Peptide Vaccine and Novel Compounds against Novel SARS-CoV-2 through Virtual Screening. Biomed Res Int 2021;2021:1596834. [PMID: 33728324 DOI: 10.1155/2021/1596834] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Sekar PC, Srinivasan E, Chandrasekhar G, Paul DM, Sanjay G, Surya S, Kumar NAR, Rajasekaran R. Probing the competitive inhibitor efficacy of frog-skin alpha helical AMPs identified against ACE2 binding to SARS-CoV-2 S1 spike protein as therapeutic scaffold to prevent COVID-19. J Mol Model 2022;28. [DOI: 10.1007/s00894-022-05117-8] [Reference Citation Analysis]
10 Ramesh M, Anand K, Shahbaaz M, Abdellattif MH. Current Perspectives in the Discovery of Newer Medications Against the Outbreak of COVID-19. Front Mol Biosci 2021;8:648232. [PMID: 34322517 DOI: 10.3389/fmolb.2021.648232] [Reference Citation Analysis]
11 Srivastava S, Chatziefthymiou SD, Kolbe M. Vaccines Targeting Numerous Coronavirus Antigens, Ensuring Broader Global Population Coverage: Multi-epitope and Multi-patch Vaccines. Methods Mol Biol 2022;2410:149-75. [PMID: 34914046 DOI: 10.1007/978-1-0716-1884-4_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Malik JA, Mulla AH, Farooqi T, Pottoo FH, Anwar S, Rengasamy KRR. Targets and strategies for vaccine development against SARS-CoV-2. Biomed Pharmacother 2021;137:111254. [PMID: 33550049 DOI: 10.1016/j.biopha.2021.111254] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
13 Liu Y, Wang K, Massoud TF, Paulmurugan R. SARS-CoV-2 Vaccine Development: An Overview and Perspectives. ACS Pharmacol Transl Sci 2020;3:844-58. [PMID: 33062951 DOI: 10.1021/acsptsci.0c00109] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
14 Prachar M, Justesen S, Steen-Jensen DB, Thorgrimsen S, Jurgons E, Winther O, Bagger FO. Identification and validation of 174 COVID-19 vaccine candidate epitopes reveals low performance of common epitope prediction tools. Sci Rep 2020;10:20465. [PMID: 33235258 DOI: 10.1038/s41598-020-77466-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
15 Ding W, Nayak J, Swapnarekha H, Abraham A, Naik B, Pelusi D. Fusion of intelligent learning for COVID-19: A state-of-the-art review and analysis on real medical data. Neurocomputing 2021;457:40-66. [PMID: 34149184 DOI: 10.1016/j.neucom.2021.06.024] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Rakib A, Sami SA, Mimi NJ, Chowdhury MM, Eva TA, Nainu F, Paul A, Shahriar A, Tareq AM, Emon NU, Chakraborty S, Shil S, Mily SJ, Ben Hadda T, Almalki FA, Emran TB. Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Comput Biol Med 2020;124:103967. [PMID: 32828069 DOI: 10.1016/j.compbiomed.2020.103967] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 15.5] [Reference Citation Analysis]
17 Bagwe PV, Bagwe PV, Ponugoti SS, Joshi SV. Peptide-Based Vaccines and Therapeutics for COVID-19. Int J Pept Res Ther 2022;28. [DOI: 10.1007/s10989-022-10397-y] [Reference Citation Analysis]
18 Alam A, Khan A, Imam N, Siddiqui MF, Waseem M, Malik MZ, Ishrat R. Design of an epitope-based peptide vaccine against the SARS-CoV-2: a vaccine-informatics approach. Brief Bioinform 2021;22:1309-23. [PMID: 33285567 DOI: 10.1093/bib/bbaa340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
19 Al Zamane S, Nobel FA, Jebin RA, Amin MB, Somadder PD, Antora NJ, Hossain MI, Islam MJ, Ahmed K, Moni MA. Development of an in silico multi-epitope vaccine against SARS-COV-2 by précised immune-informatics approaches. Inform Med Unlocked 2021;27:100781. [PMID: 34746365 DOI: 10.1016/j.imu.2021.100781] [Reference Citation Analysis]
20 Jakhar R, Gakhar SK. An Immunoinformatics Study to Predict Epitopes in the Envelope Protein of SARS-CoV-2. Can J Infect Dis Med Microbiol 2020;2020:7079356. [PMID: 33299503 DOI: 10.1155/2020/7079356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Singh SP, Pritam M, Pandey B, Yadav TP. Microstructure, pathophysiology, and potential therapeutics of COVID-19: A comprehensive review. J Med Virol 2021;93:275-99. [PMID: 32617987 DOI: 10.1002/jmv.26254] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
22 ElBagoury M, Tolba MM, Nasser HA, Jabbar A, Elagouz AM, Aktham Y, Hutchinson A. The find of COVID-19 vaccine: Challenges and opportunities. J Infect Public Health 2021;14:389-416. [PMID: 33647555 DOI: 10.1016/j.jiph.2020.12.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
23 Akhtar N, Joshi A, Kaushik V, Kumar M, Mannan MA. In-silico design of a multivalent epitope-based vaccine against Candida auris. Microb Pathog 2021;155:104879. [PMID: 33848597 DOI: 10.1016/j.micpath.2021.104879] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
24 Hamley IW. Peptides for Vaccine Development. ACS Appl Bio Mater 2022. [PMID: 35195008 DOI: 10.1021/acsabm.1c01238] [Reference Citation Analysis]
25 Khan MT, Islam MJ, Parihar A, Islam R, Jerin TJ, Dhote R, Ali MA, Laura FK, Halim MA. Immunoinformatics and molecular modeling approach to design universal multi-epitope vaccine for SARS-CoV-2. Inform Med Unlocked 2021;24:100578. [PMID: 33898733 DOI: 10.1016/j.imu.2021.100578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
26 Tahir Ul Qamar M, Shahid F, Aslam S, Ashfaq UA, Aslam S, Fatima I, Fareed MM, Zohaib A, Chen LL. Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2. Infect Dis Poverty 2020;9:132. [PMID: 32938504 DOI: 10.1186/s40249-020-00752-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
27 Nguyen A, David JK, Maden SK, Wood MA, Weeder BR, Nellore A, Thompson RF. Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2. J Virol. 2020;94:e00510-20. [PMID: 32303592 DOI: 10.1128/jvi.00510-20] [Cited by in Crossref: 204] [Cited by in F6Publishing: 152] [Article Influence: 102.0] [Reference Citation Analysis]
28 Islam SS, Midya S, Sinha S, Saadi SMAI. Natural medicinal plant products as an immune-boosters: A possible role to lessen the impact of Covid-19. Case Studies in Chemical and Environmental Engineering 2021;4:100105. [DOI: 10.1016/j.cscee.2021.100105] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
29 Rezaei S, Sefidbakht Y, Uskoković V. Tracking the pipeline: immunoinformatics and the COVID-19 vaccine design. Brief Bioinform 2021:bbab241. [PMID: 34219142 DOI: 10.1093/bib/bbab241] [Reference Citation Analysis]
30 Sekar PC, Rajasekaran R. Could Dermaseptin Analogue be a Competitive Inhibitor for ACE2 Towards Binding with Viral Spike Protein Causing COVID19?: Computational Investigation. Int J Pept Res Ther 2021;:1-14. [PMID: 33488318 DOI: 10.1007/s10989-020-10149-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
31 Waqas M, Haider A, Sufyan M, Siraj S, Sehgal SA. Determine the Potential Epitope Based Peptide Vaccine Against Novel SARS-CoV-2 Targeting Structural Proteins Using Immunoinformatics Approaches. Front Mol Biosci 2020;7:227. [PMID: 33195402 DOI: 10.3389/fmolb.2020.00227] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
32 Rahman MS, Hoque MN, Islam MR, Akter S, Rubayet Ul Alam ASM, Siddique MA, Saha O, Rahaman MM, Sultana M, Crandall KA, Hossain MA. Epitope-based chimeric peptide vaccine design against S, M and E proteins of SARS-CoV-2, the etiologic agent of COVID-19 pandemic: an in silico approach. PeerJ 2020;8:e9572. [PMID: 33194329 DOI: 10.7717/peerj.9572] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 17.5] [Reference Citation Analysis]
33 Stavropoulou E, Bezirtzoglou E. Probiotics as a Weapon in the Fight Against COVID-19. Front Nutr 2020;7:614986. [PMID: 33385008 DOI: 10.3389/fnut.2020.614986] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
34 Soleimanpour S, Yaghoubi A. COVID-19 vaccine: where are we now and where should we go? Expert Rev Vaccines 2021;20:23-44. [PMID: 33435774 DOI: 10.1080/14760584.2021.1875824] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
35 Sohail MS, Ahmed SF, Quadeer AA, McKay MR. In silico T cell epitope identification for SARS-CoV-2: Progress and perspectives. Adv Drug Deliv Rev 2021;171:29-47. [PMID: 33465451 DOI: 10.1016/j.addr.2021.01.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 33.0] [Reference Citation Analysis]
36 Batool H, Batool S, Mahmood MS, Mushtaq N, Khan AU, Ali M, Sahibzada KI, Ashraf NM. Prediction of putative epitope-based vaccine against all corona virus strains for the Chinese population: Approach toward development of vaccine. Microbiol Immunol 2021;65:154-60. [PMID: 33295677 DOI: 10.1111/1348-0421.12866] [Reference Citation Analysis]
37 Mobini Kesheh M, Shavandi S, Hosseini P, Kakavand-Ghalehnoei R, Keyvani H. Bioinformatic HLA Studies in the Context of SARS-CoV-2 Pandemic and Review on Association of HLA Alleles with Preexisting Medical Conditions. Biomed Res Int 2021;2021:6693909. [PMID: 34136572 DOI: 10.1155/2021/6693909] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Safavi A, Kefayat A, Mahdevar E, Abiri A, Ghahremani F. Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches. Vaccine 2020;38:7612-28. [PMID: 33082015 DOI: 10.1016/j.vaccine.2020.10.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
39 Lundstrom K. The Current Status of COVID-19 Vaccines. Front Genome Ed 2020;2:579297. [PMID: 34713220 DOI: 10.3389/fgeed.2020.579297] [Cited by in Crossref: 9] [Article Influence: 9.0] [Reference Citation Analysis]
40 Shukla P, Pandey P, Prasad B, Robinson T, Purohit R, D'Cruz LG, Tambuwala MM, Mutreja A, Harkin J, Rai TS, Murray EK, Gibson DS, Bjourson AJ. Immuno-informatics analysis predicts B and T cell consensus epitopes for designing peptide vaccine against SARS-CoV-2 with 99.82% global population coverage. Brief Bioinform 2021:bbab496. [PMID: 34962259 DOI: 10.1093/bib/bbab496] [Reference Citation Analysis]
41 Viana Invenção MDC, Melo ARDS, de Macêdo LS, da Costa Neves TSP, de Melo CML, Cordeiro MN, de Aragão Batista MV, de Freitas AC. Development of synthetic antigen vaccines for COVID-19. Hum Vaccin Immunother 2021;:1-16. [PMID: 34613880 DOI: 10.1080/21645515.2021.1974288] [Reference Citation Analysis]
42 Tilocca B, Britti D, Urbani A, Roncada P. Computational Immune Proteomics Approach to Target COVID-19. J Proteome Res 2020;19:4233-41. [PMID: 32914632 DOI: 10.1021/acs.jproteome.0c00553] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
43 Chen J, Deng Y, Huang B, Han D, Wang W, Huang M, Zhai C, Zhao Z, Yang R, Zhao Y, Wang W, Zhai D, Tan W. DNA Vaccines Expressing the Envelope and Membrane Proteins Provide Partial Protection Against SARS-CoV-2 in Mice. Front Immunol 2022;13:827605. [PMID: 35281016 DOI: 10.3389/fimmu.2022.827605] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Chauhan N, Soni S, Gupta A, Aslam M, Jain U. Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review. J Med Virol 2021;93:1967-82. [PMID: 33270225 DOI: 10.1002/jmv.26709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
45 Bai C, Zhong Q, Gao GF. Overview of SARS-CoV-2 genome-encoded proteins. Sci China Life Sci 2021. [PMID: 34387838 DOI: 10.1007/s11427-021-1964-4] [Reference Citation Analysis]
46 Syeda HB, Syed M, Sexton KW, Syed S, Begum S, Syed F, Prior F, Yu F Jr. Role of Machine Learning Techniques to Tackle the COVID-19 Crisis: Systematic Review. JMIR Med Inform 2021;9:e23811. [PMID: 33326405 DOI: 10.2196/23811] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 13.0] [Reference Citation Analysis]
47 Khavinson V, Linkova N, Dyatlova A, Kuznik B, Umnov R. Peptides: Prospects for Use in the Treatment of COVID-19. Molecules 2020;25:E4389. [PMID: 32987757 DOI: 10.3390/molecules25194389] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
48 Piadel K, Haybatollahi A, Dalgleish AG, Smith PL. Selection and T-cell antigenicity of synthetic long peptides derived from SARS-CoV-2. J Gen Virol 2022;103. [PMID: 35014605 DOI: 10.1099/jgv.0.001698] [Reference Citation Analysis]
49 Biswas S, Manna S, Nandy A, Basak SC. New Computational Approach for Peptide Vaccine Design Against SARS-COV-2. Int J Pept Res Ther 2021;:1-17. [PMID: 34276265 DOI: 10.1007/s10989-021-10251-7] [Reference Citation Analysis]
50 Park KS, Sun X, Aikins ME, Moon JJ. Non-viral COVID-19 vaccine delivery systems. Adv Drug Deliv Rev 2021;169:137-51. [PMID: 33340620 DOI: 10.1016/j.addr.2020.12.008] [Cited by in Crossref: 92] [Cited by in F6Publishing: 64] [Article Influence: 92.0] [Reference Citation Analysis]
51 Hoque MN, Chaudhury A, Akanda MAM, Hossain MA, Islam MT. Genomic diversity and evolution, diagnosis, prevention, and therapeutics of the pandemic COVID-19 disease. PeerJ 2020;8:e9689. [PMID: 33005486 DOI: 10.7717/peerj.9689] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
52 Bose T, Pant N, Pinna NK, Bhar S, Dutta A, Mande SS. Does immune recognition of SARS-CoV2 epitopes vary between different ethnic groups? Virus Res 2021;305:198579. [PMID: 34560183 DOI: 10.1016/j.virusres.2021.198579] [Reference Citation Analysis]
53 Madhavan M, AlOmair LA, Ks D, Mustafa S. Exploring peptide studies related to SARS-CoV to accelerate the development of novel therapeutic and prophylactic solutions against COVID-19. J Infect Public Health 2021;14:1106-19. [PMID: 34280732 DOI: 10.1016/j.jiph.2021.06.017] [Reference Citation Analysis]
54 Humayun F, Cai Y, Khan A, Farhan SA, Khan F, Rana UI, Qamar AB, Fawad N, Shamas S, Dongqing-Wei. Structure-guided design of multi-epitopes vaccine against variants of concern (VOCs) of SARS-CoV-2 and validation through In silico cloning and immune simulations. Comput Biol Med 2021;140:105122. [PMID: 34896886 DOI: 10.1016/j.compbiomed.2021.105122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Chukwudozie OS, Duru VC, Ndiribe CC, Aborode AT, Oyebanji VO, Emikpe BO. The Relevance of Bioinformatics Applications in the Discovery of Vaccine Candidates and Potential Drugs for COVID-19 Treatment. Bioinform Biol Insights 2021;15:11779322211002168. [PMID: 33795932 DOI: 10.1177/11779322211002168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
56 Khavinson V, Terekhov A, Kormilets D, Maryanovich A. Homology between SARS CoV-2 and human proteins. Sci Rep 2021;11:17199. [PMID: 34433832 DOI: 10.1038/s41598-021-96233-7] [Reference Citation Analysis]
57 Fatoba AJ, Adeleke VT, Maharaj L, Okpeku M, Adeniyi AA, Adeleke MA. Design of a Multiepitope Vaccine against Chicken Anemia Virus Disease. Viruses 2022;14:1456. [DOI: 10.3390/v14071456] [Reference Citation Analysis]
58 Di Natale C, La Manna S, De Benedictis I, Brandi P, Marasco D. Perspectives in Peptide-Based Vaccination Strategies for Syndrome Coronavirus 2 Pandemic. Front Pharmacol 2020;11:578382. [PMID: 33343349 DOI: 10.3389/fphar.2020.578382] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
59 Yadav T, Srivastava N, Mishra G, Dhama K, Kumar S, Puri B, Saxena SK. Recombinant vaccines for COVID-19. Hum Vaccin Immunother 2020;16:2905-12. [PMID: 33232211 DOI: 10.1080/21645515.2020.1820808] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
60 Bhuiyan FR, Howlader S, Raihan T, Hasan M. Plants Metabolites: Possibility of Natural Therapeutics Against the COVID-19 Pandemic. Front Med (Lausanne) 2020;7:444. [PMID: 32850918 DOI: 10.3389/fmed.2020.00444] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
61 Tan Y, Tang F. SARS-CoV-2-mediated immune system activation and potential application in immunotherapy. Med Res Rev 2021;41:1167-94. [PMID: 33185926 DOI: 10.1002/med.21756] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
62 Akhand MRN, Azim KF, Hoque SF, Moli MA, Joy BD, Akter H, Afif IK, Ahmed N, Hasan M. Genome based evolutionary lineage of SARS-CoV-2 towards the development of novel chimeric vaccine. Infect Genet Evol 2020;85:104517. [PMID: 32882432 DOI: 10.1016/j.meegid.2020.104517] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
63 Kibria KMK, Faruque MO, Islam MSB, Ullah H, Mahmud S, Miah M, Saleh AA. A conserved subunit vaccine designed against SARS-CoV-2 variants showed evidence in neutralizing the virus. Appl Microbiol Biotechnol 2022. [PMID: 35612630 DOI: 10.1007/s00253-022-11988-x] [Reference Citation Analysis]
64 Srivastava S, Verma S, Kamthania M, Agarwal D, Saxena AK, Kolbe M, Singh S, Kotnis A, Rathi B, Nayar SA, Shin HJ, Vashisht K, Pandey KC. Computationally validated SARS-CoV-2 CTL and HTL Multi-Patch vaccines, designed by reverse epitomics approach, show potential to cover large ethnically distributed human population worldwide. J Biomol Struct Dyn 2020;:1-20. [PMID: 33155524 DOI: 10.1080/07391102.2020.1838329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
65 Kumar N, Sood D, Chandra R. Design and optimization of a subunit vaccine targeting COVID-19 molecular shreds using an immunoinformatics framework. RSC Adv 2020;10:35856-72. [DOI: 10.1039/d0ra06849g] [Cited by in Crossref: 7] [Article Influence: 3.5] [Reference Citation Analysis]